Hong Kong · Delayed Price · Currency is HKD Shandong Boan Biotechnology Company Description
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China.
The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal women with osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone.
It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit α; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial.
It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins.
The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
| Country | China |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 760 |
| CEO | Hua Jiang |
Contact Details
Address: No. 39 Keji Avenue Yantai China | |
| Phone | 86 53 5437 9111 |
| Website | boan-bio.com |
Stock Details
| Ticker Symbol | 6955 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hua Jiang | Executive Chairlady and Chief Executive Officer |
| Dr. Changlin Dou | Chief Operating Officer, President of Research & Development and Executive Director |
| Shenghan Wang | Chief Financial Officer and Executive Director |
| Deyong Song | Head of Biopharmaceutical Research and Discovery Department |
| Chunna You | Senior Vice President of Research & Development Center |
| Zhou Ming | Chief Medical Officer |
| Siu Kuen Lai FCIS, FCS | Company Secretary |